1) Strategy & Leadership
- Andrew Hider, CEO, emphasized a focus on executing a turnaround strategy, which includes stabilizing the business, strengthening the balance sheet, and fostering a culture of continuous improvement.
- The company is actively searching for a permanent CFO to replace Joel, who has left the company.
- Baxter has launched the Baxter Growth and Performance System (GPS) to enhance operational efficiency and accountability across the organization.

2) Financial & Segment Results
- Q1 2026 global sales from continuing operations totaled $2.7 billion, a 3% increase YoY but a 1% decline on an organic basis.
- Adjusted earnings from continuing operations were $0.36 per share, down 35% YoY.
- Segment performance highlights:
- Medical Products & Therapy (MPT): Sales of $1.3 billion, down 2%; Infusion Therapies and Technologies (ITT) sales were $981 million, down 5% due to Novum LVP shipment holds.
- Healthcare Systems & Technology (HST): Sales of $705 million, down 2%; Front Line Care sales were $270 million, down 4%.
- Pharmaceuticals: Sales of $621 million, up 1%; Injectables and Anesthesia sales were $301 million, down 13% due to supply constraints.

3) Problems / Headwinds
- The company faced significant headwinds from tariffs, higher manufacturing costs, and the ongoing shipment and installation hold of the Novum LVP, which impacted sales and margins.
- Adjusted operating margins decreased across all segments due to unfavorable year-over-year comparisons and increased costs.
- Supply chain challenges, particularly in the Injectables and Anesthesia segments, are expected to persist into 2027.

4) Operational or Product Plans
- Baxter is focusing on innovation, with new product launches such as the Dynamo smart hospital stretcher and the IV Verified Line labeling system.
- The company is working to resolve issues related to the Novum LVP and is preparing for necessary regulatory submissions once hardware and software corrections are finalized.
- Baxter aims to improve free cash flow and reduce leverage, targeting a net leverage ratio of approximately 3x by the end of 2026.

5) Guidance & Outlook / Investor Angle
- Baxter reiterated its full-year 2026 guidance, expecting total sales growth to be flat to 1% on a reported basis, with organic sales growth anticipated to be flat.
- The company expects a challenging first half of the year, with improvement anticipated in the second half, driven by new product launches and improved operational performance.
- Free cash flow is expected to be back half-weighted, consistent with 2025, reflecting normal seasonality and the expected benefits from recent cost structure actions.

Bottom line: Baxter is navigating a challenging environment with a focus on stabilizing operations and driving innovation. While Q1 results were in line with expectations, the company faces headwinds that may impact growth in the near term. However, management is confident in the long-term potential and is taking steps to enhance shareholder value through improved operational efficiency and strategic investments.